🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Itepekimab, Matched Placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  2. Itepekimab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  3. Itepekimab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  4. Ivabradine Anpharm 5 mg film-coated tablets, Placebo: lactose monohydrate, microcrystalline cellulose, native corn starch, colloidal anhydrous silica, maltodextrin, magnesium stearate Capsule: Beef gelatin, Glycerol, Titanium dioxide

    COLLEGIUM PHARMACEUTICAL, INC

    Myocardial Injury after Noncardiac Surgery

    phase 3 small molecule active

    1 trial

  5. JNJ 67896062, Matching Placebo for Macitentan 75 mg, JNJ 67896062, Matching Placebo for Macitentan 37.5 mg, Opsumit 10 mg film-coated tablets, Matching Placebo for Macitentan 10 mg

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  6. JNJ-56021927, Prednison acis 5 mg, Tabletten, ZYTIGA 250 mg tablets, placebo to match JNJ-56021927/Apalutamide, -

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  7. JNJ-77242113, Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  8. JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  9. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  10. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Sjögren's Disease

    phase 3 small molecule active

    1 trial

  11. JNT-517 Placebo, JNT-517, JNT-517

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  12. JX10, Jx10 placebo drug product is prepared as a sterile, lyophilized white to light yellow cake or powder for infusion.

    Lacuna Pharma Pty Ltd

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  13. Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517

    Boehringer Ingelheim

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  14. Jardiance 10 mg film-coated tablets, empagliflozin, Placebo matching empagliflozin, film-coated tablets

    Boehringer Ingelheim

    Chronic kidney disease in paediatric patients

    phase 3 small molecule active

    1 trial

  15. KEYTRUDA 25 mg/mL concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab, Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 3 small molecule active

    1 trial

  16. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Placebo to MK-1084 25 MG, MK-1084, Placebo to MK-1084 50 mg, MK-1084

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  17. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Placebo to MK-3475, CISPLATIN , GEMCITABINE

    Merck Sharp and Dohme

    Biliary Tract Carcinoma

    phase 3 small molecule active

    1 trial

  18. Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation”

    Kamada BioPharma Limited at Fieldfisher LLP

    Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.

    phase 3 small molecule active

    1 trial

  19. KarX-EC, KarX-EC, KarX-EC matching placebo, KarXT, KarXT, KarX-EC, KarX-EC, KarXT matching placebo, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  20. KarX-EC, KarXT, KarX-EC matching placebo, KarX-EC, KarXT, KarXT, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  21. KarXT, KarX-EC matching Placebo, KarX-EC, KarXT matching Placebo, KarXT, KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  22. KarXT, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC matching Placebo, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  23. KarXT, KarXT Matching Placebo, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule active

    1 trial

  24. KarXT, KarXT, KarXT, KarXT Matching Placebo

    Bristol-Myers Squibb Australia Pty Ltd

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources